{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:14:36Z","timestamp":1791486876784,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170186, 82370193, 81720108002"],"award-info":[{"award-number":["82170186, 82370193, 81720108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170186, 82370193, 81720108002"],"award-info":[{"award-number":["82170186, 82370193, 81720108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Province Capability Improvement Project through Science, Technology and Education","award":["ZDXK202209"],"award-info":[{"award-number":["ZDXK202209"]}]},{"name":"Jiangsu Province Capability Improvement Project through Science, Technology and Education","award":["ZDXK202209"],"award-info":[{"award-number":["ZDXK202209"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M691336"],"award-info":[{"award-number":["2021M691336"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010246","name":"Postdoctoral Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["2021K083A"],"award-info":[{"award-number":["2021K083A"]}],"id":[{"id":"10.13039\/501100010246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aimed to characterize the clinical characteristics, treatment patterns, survival outcomes, and prognostic factors of Chinese patients with primary mediastinal B-cell lymphoma (PMBCL). We retrospectively reviewed 69 consecutive patients with PMBCL treated at our center between 2010 and 2025. External validation was performed using data from the Surveillance, Epidemiology, and End Results (SEER) database (n\u2009=\u20091,460). The median age at diagnosis was 33 years (range, 18\u201362), with a female predominance (female-to-male ratio, 2.1:1). Most patients (92.8%, 64\/69) received R-DA-EPOCH as frontline therapy, and 29.0% (20\/69) additionally underwent consolidative radiotherapy (RT). Among 51 evaluable patients, the objective response rate was 90.2%, with a complete response rate of 74.5%. After a median follow-up of 74 months (range, 2\u2013166), the estimated 5-year progression-free survival (PFS) and overall survival (OS) rates in whole cohort were 88.7% and 94.8%, respectively. Hematologic toxicity, predominantly febrile neutropenia, was the most common adverse event; nevertheless, 60.4% of patients maintained a relative dose intensity\u2009\u2265\u2009100%. Consolidative RT did not confer a survival advantage, whereas age\u2009&gt;\u200940 years emerged as an adverse prognostic factor for OS, a finding further validated in the SEER cohort. Chinese patients with PMBCL generally have favorable outcomes in the modern treatment era. However, older age (&gt;\u200940 years) is associated with inferior survival. The R-DA-EPOCH regimen demonstrated high efficacy in this real-world setting, whereas additionally consolidative RT failed to provide a significant survival benefit.<\/jats:p>","DOI":"10.1007\/s00277-026-06914-4","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:12:47Z","timestamp":1772255567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real world outcomes and prognostic factors in Chinese patients with primary mediastinal B cell lymphoma: A single center experience and the Surveillance, Epidemiology, and End Results validation"],"prefix":"10.1007","volume":"105","author":[{"given":"Boya","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruize","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonglu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"11","key":"6914_CR1","doi-asserted-by":"publisher","first-page":"e865","DOI":"10.1016\/j.clml.2021.06.012","volume":"21","author":"Z Ahmed","year":"2021","unstructured":"Ahmed Z et al (2021) Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics. Clin Lymphoma Myeloma Leuk 21(11):e865\u2013e875","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"6914_CR2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.2020008376","volume":"140","author":"KJ Savage","year":"2022","unstructured":"Savage KJ (2022) Primary mediastinal large B-cell lymphoma. Blood 140(9):955\u2013970","journal-title":"Blood"},{"issue":"1","key":"6914_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bjh.15778","volume":"185","author":"C Lees","year":"2019","unstructured":"Lees C et al (2019) Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol 185(1):25\u201341","journal-title":"Br J Haematol"},{"issue":"19","key":"6914_CR4","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1182\/bloodadvances.2021004778","volume":"5","author":"V Camus","year":"2021","unstructured":"Camus V et al (2021) Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. Blood Adv 5(19):3862\u20133872","journal-title":"Blood Adv"},{"issue":"2","key":"6914_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/ejh.13715","volume":"108","author":"AC Freitas","year":"2021","unstructured":"Freitas AC et al (2021) End of treatment FDG-PET in primary mediastinal B\u2010cell lymphoma treated with R\u2010chemotherapy: Prognostic indicator and implications for consolidation radiotherapy. Eur J Haematol 108(2):118\u2013124","journal-title":"Eur J Haematol"},{"issue":"21","key":"6914_CR6","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1111\/1759-7714.14155","volume":"12","author":"Y Yu","year":"2021","unstructured":"Yu Y et al (2021) Primary mediastinal large B cell lymphoma. Thorac Cancer 12(21):2831\u20132837","journal-title":"Thorac Cancer"},{"issue":"1","key":"6914_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12885-017-3332-3","volume":"17","author":"K Lisenko","year":"2017","unstructured":"Lisenko K et al (2017) Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. BMC Cancer 17(1):359","journal-title":"BMC Cancer"},{"issue":"12","key":"6914_CR8","first-page":"1258","volume":"87","author":"PL Zinzani","year":"2002","unstructured":"Zinzani PL et al (2002) Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 87(12):1258\u20131264","journal-title":"Haematologica"},{"issue":"2","key":"6914_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/sj.bjc.6601460","volume":"90","author":"G Todeschini","year":"2004","unstructured":"Todeschini G et al (2004) Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B\/VACOP-B. Br J Cancer 90(2):372\u2013376","journal-title":"Br J Cancer"},{"issue":"2","key":"6914_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1634\/theoncologist.2011-0275","volume":"17","author":"TP Vassilakopoulos","year":"2012","unstructured":"Vassilakopoulos TP et al (2012) Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 17(2):239\u2013249","journal-title":"Oncologist"},{"issue":"3","key":"6914_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3109\/10428194.2013.810738","volume":"55","author":"JD Soumerai","year":"2014","unstructured":"Soumerai JD et al (2014) Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 55(3):538\u2013543","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"6914_CR12","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1182\/blood.2025028823","volume":"146","author":"E Zucca","year":"2025","unstructured":"Zucca E et al (2025) Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial. Blood 146(23):2758\u20132764","journal-title":"Blood"},{"issue":"1","key":"6914_CR13","first-page":"98","volume":"45","author":"LW Chen","year":"2024","unstructured":"Chen LW, Li JY, Fan L (2024) Progress in treatment of primary mediastinal large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi 45(1):98\u2013102","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"15","key":"6914_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408\u20131416","journal-title":"N Engl J Med"},{"issue":"5","key":"6914_CR15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.14951","volume":"179","author":"L Giulino-Roth","year":"2017","unstructured":"Giulino-Roth L et al (2017) Outcomes of adults and children with primary mediastinal B\u2010cell lymphoma treated with dose\u2010adjusted EPOCH\u2010R. Br J Haematol 179(5):739\u2013747","journal-title":"Br J Haematol"},{"key":"6914_CR16","doi-asserted-by":"publisher","first-page":"102898","DOI":"10.1016\/j.ctrv.2025.102898","volume":"134","author":"L Donzelli","year":"2025","unstructured":"Donzelli L et al (2025) Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies. Cancer Treat Rev 134:102898","journal-title":"Cancer Treat Rev"},{"issue":"24","key":"6914_CR17","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1182\/blood.2019004296","volume":"136","author":"AR Hayden","year":"2020","unstructured":"Hayden AR et al (2020) Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood 136(24):2803\u20132811","journal-title":"Blood"},{"issue":"S2","key":"6914_CR18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/hon.135_2631","volume":"37","author":"E Derenzini","year":"2019","unstructured":"Derenzini E et al (2019) Predictive Value of End-of\u2010Treatment Positron Emission Tomography Scan after Da\u2010Epoch\u2010R in Primary Mediastinal B\u2010Cell Lymphoma. Real\u2010Life Experience. Hematol Oncol 37(S2):458\u2013459","journal-title":"Hematol Oncol"},{"issue":"S2","key":"6914_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/hon.77_2630","volume":"37","author":"M Trneny","year":"2019","unstructured":"Trneny M et al (2019) Is It Radiotherapy Necessary for Primary Mediastinal B-Cell Lymphoma (Pmbl) Patients Achieving Pet Negativity after Immunochemotherapy? Hematol Oncol 37(S2):267\u2013268","journal-title":"Hematol Oncol"},{"issue":"34","key":"6914_CR20","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/JCO-24-01373","volume":"42","author":"M Martelli","year":"2024","unstructured":"Martelli M et al (2024) Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. J Clin Oncol 42(34):4071\u20134083","journal-title":"J Clin Oncol"},{"key":"6914_CR21","unstructured":"Zelenetz AD et al (2025) NCCN Guidelines\u00ae Insights: B-Cell Lymphomas 3.2025. J Natl Compr Canc Netw. 2025;23(10):e250048"},{"issue":"7","key":"6914_CR22","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7):1720\u20131748","journal-title":"Leukemia"},{"issue":"27","key":"6914_CR23","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"6","key":"6914_CR24","first-page":"491","volume":"35","author":"J Wang","year":"2014","unstructured":"Wang J et al (2014) [Clinical analysis of 82 cases of primary mediastinal large B cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi 35(6):491\u2013494","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"6914_CR25","unstructured":"Rao HL, Wang Z (2024) [Introduction on the update of the 5th edition WHO classifications of B-cell neoplasms]. Zhonghua Bing Li Xue Za Zhi, 53(1): pp. 6\u201311"},{"key":"6914_CR26","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","volume":"110","author":"S Poletto","year":"2022","unstructured":"Poletto S et al (2022) Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev 110:102443","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"6914_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M et al (2022) Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study. Br J Haematol 198(5):847\u2013860","journal-title":"Br J Haematol"},{"issue":"3","key":"6914_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ et al (2022) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 33(3):259\u2013275","journal-title":"Ann Oncol"},{"issue":"30","key":"6914_CR29","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA et al (2018) Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 36(30):3043\u20133054","journal-title":"J Clin Oncol"},{"issue":"9","key":"6914_CR30","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1182\/bloodadvances.2024015577","volume":"9","author":"V Camus","year":"2025","unstructured":"Camus V et al (2025) Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma. Blood Adv 9(9):2232\u20132246","journal-title":"Blood Adv"},{"key":"6914_CR31","doi-asserted-by":"crossref","unstructured":"Noel R et al (2025) Long-Term Outcomes and Management Strategies With DA\u2010R\u2010EPOCH in Primary Mediastinal B\u2010Cell Lymphoma: Insights From a Single\u2010Center Experience. Hematol Oncol. 2025;43(3):e70060","DOI":"10.1002\/hon.70060"},{"issue":"7","key":"6914_CR32","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00277-023-05225-2","volume":"102","author":"H Zhou","year":"2023","unstructured":"Zhou H et al (2023) Primary mediastinal\/thymic diffuse large B-cell lymphoma: a population-based study on incidence and survival. Ann Hematol 102(7):1879\u20131886","journal-title":"Ann Hematol"},{"issue":"8","key":"6914_CR33","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","volume":"99","author":"WH Wilson","year":"2002","unstructured":"Wilson WH et al (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 99(8):2685\u20132693","journal-title":"Blood"},{"issue":"1","key":"6914_CR34","doi-asserted-by":"publisher","first-page":"e3242","DOI":"10.1002\/hon.3242","volume":"42","author":"M Picardi","year":"2024","unstructured":"Picardi M et al (2024) Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma. Hematol Oncol 42(1):e3242","journal-title":"Hematol Oncol"},{"issue":"6","key":"6914_CR35","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00277-022-04806-x","volume":"101","author":"D Gramegna","year":"2022","unstructured":"Gramegna D et al (2022) The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation. Ann Hematol 101(6):1227\u20131237","journal-title":"Ann Hematol"},{"issue":"10","key":"6914_CR36","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1016\/S2352-3026(23)00212-0","volume":"10","author":"T Trab","year":"2023","unstructured":"Trab T et al (2023) Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study. Lancet Haematol 10(10):e838\u2013e848","journal-title":"Lancet Haematol"},{"issue":"3","key":"6914_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/bjh.12038","volume":"159","author":"AY Minn","year":"2012","unstructured":"Minn AY et al (2012) Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory\/relapsed Hodgkin lymphoma. Br J Haematol 159(3):329\u2013339","journal-title":"Br J Haematol"},{"issue":"31","key":"6914_CR38","doi-asserted-by":"publisher","first-page":"7994","DOI":"10.1200\/JCO.2005.01.9083","volume":"23","author":"DL Forrest","year":"2005","unstructured":"Forrest DL et al (2005) High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin\u2019s Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation. J Clin Oncol 23(31):7994\u20138002","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06914-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06914-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06914-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:04:02Z","timestamp":1781636642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06914-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6914"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06914-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors read and approved the manuscript as submitted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No previously published material was reproduced in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to Reproduce Material From Other Sources"}},{"value":"Patients were not included in any clinical trial.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Registration (including trial number)"}},{"value":"This study was proved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University and performed in accordance with the Declaration of Helsinki.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients had given written informed consent for collection and use of data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare that they have no competing interests.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"147"}}